• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Ispire Technology Inc.

    6/28/24 5:00:11 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email
    false 0001948455 0001948455 2024-06-25 2024-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 25, 2024

     

    Ispire Technology Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41680   84-5106049
    (State or other jurisdiction of
    incorporation or organization)
      (Commission file number)   (IRS Employer
    Identification No.)

     

    19700 Magellan Drive

    Los Angeles, CA 90502

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (310) 742-9975

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, par value $0.0001 per share   ISPR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Rouhani Employment Agreement

     

    On June 25, 2024, Ispire Technology Inc. (the “Company”) entered into an executive employment agreement with Mr. Tirdad Rouhani, the Company’s President (the “Rouhani Agreement”). The Rouhani agreement has a three-year term and continues on a year-to-year basis unless terminated by either the Company or Mr. Rouhani on written notice given not later than 180 days prior to the expiration of the initial term or any one-year extension. Mr. Rouhani will receive an annual base salary of $410,000, which may be increased from time to time, but not decreased, during the term of the Rouhani Agreement. Mr. Rouhani is eligible for an annual discretionary bonus with a bonus target of 50% of his annual base salary, subject to the discretion of the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”). Mr. Rouhani is eligible for any fringe benefits offered by the company on the same terms and conditions as other executives, including group health benefits and a 401k retirement plan. In the event Mr. Rouhani is terminated without Cause or resigns for Good Reason, Mr. Rouhani is entitled to severance in the amount of twelve months’ then-applicable base salary and immediate accelerated vesting of 50% of any unvested Equity Grants (as that term is defined in the Company’s 2020 Equity Incentive Plan (the “Plan”)) that Mr. Rouhani has received under the Plan, regardless of the terms of the Plan or any award agreement. The Rouhani Agreement contains customary assignment of invention and confidentiality provisions.

     

    The foregoing description of the Rouhani Agreement does not purport to be complete and is qualified in its entirety by reference to the Rouhani Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K.

     

    Przybyla Employment Agreement

     

    On June 25, 2024, the Company entered into an executive employment agreement with Mr. Steven Przybyla, the Company’s Chief Legal Officer and Secretary (the “Przybyla Agreement”). Mr. Przybyla’s employment with the Company is at will and may be terminated by either Mr. Przybyla or the Company at any time, for any reason, or no reason. Mr. Przybyla will receive an annual base salary of $400,000, which may be increased from time to time, but not decreased, during the term of his employment. Mr. Przybyla is eligible for an annual discretionary bonus with a bonus target of 50% of his annual base salary, subject to the discretion of the Compensation Committee. Mr. Pzybyla is eligible for any fringe benefits offered by the company on the same terms and conditions as other executives, including group health benefits and a 401k retirement plan. The Company has agreed to bear the costs associated with Mr. Pzybyla’s maintenance of his professional licenses. In the event Mr. Przybyla is terminated without Cause or resigns for Good Reason, Mr. Przybyla is entitled to severance in the amount of twelve months’ then-applicable base salary and immediate accelerated vesting of 50% of any unvested Equity Grants (as that term is defined in the Plan) that Mr. Przybyla has received under the Plan, regardless of the terms of the Plan or any award agreement. The Przybyla Agreement contains customary assignment of invention and confidentiality provisions.

     

    The foregoing description of the Przybyla Agreement does not purport to be complete and is qualified in its entirety by reference to the Przybyla Agreement, which is attached as Exhibit 10.2 to this Current Report on Form 8-K.

     

    1

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    The Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 25, 2024. On May 1, 2024, the record date for the Annual Meeting, there were 56,338,834 shares of the Company’s common stock issued and outstanding with each such share being entitled to one vote.

     

    A total of 40,242,706 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, as applicable, with respect to each matter is set forth below.

     

    Proposal 1: Election of Directors

     

    The stockholders elected each of Tuanfang Liu, Jiangyan Zhu, Christopher Robert Burch, Brent Cox, and John Fargis, each to serve for a one-year term until the conclusion of the 2025 Annual Meeting of Stockholders or until their successors is duly elected and qualified.

     

    Nominee   Votes For   Votes Against   Votes Abstained   Broker Non-Votes
    Tuanfang Liu   34,381,435   599,570   2,018   5,259,683
    Jiangyan Zhu   34,861,670   119,337   2,016   5,259,683
    Christopher Robert Burch   34,924,706   56,304   2,013   5,259,683
    Brent Cox   34,774,848   206,158   2,017   5,259,683
    John Fargis   34,788,266   192,739   2,018   5,259,683

     

    Proposal 2: Proposal to Ratify the Appointment by the Audit Committee of the Company’s Board of Directors of Marcum LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending June 30, 2024

     

    The stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024.

     

    Votes For   Votes Against   Votes Abstained
    40,241,697   995   14

     

    2

     

     

    Proposal 3: Advisory Vote on 2023 Executive Compensation

     

    The stockholders approved the non-binding advisory resolution approving the compensation of the Company’s named executive officers.

     

    Votes For   Votes Against   Votes Abstained   Broker Non-Votes
    34,971,080   8,228   3,715   5,259,683

     

    Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation

     

    The stockholders voted in favor of “3 Year” as their preferred frequency for holding future advisory votes to approve the compensation of the Company’s named executive officers.

     

    1 Year   2 Years   3 Years   Votes Abstained   Broker Non-Votes
    1,501,987   20   33,480,999   17   5,259,683

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits. The following exhibits are filed with this Form 8-K:

     

    Exhibit No.   Description
    10.1   Executive Employment Agreement dated June 25, 2024, by and between Ispire Technology Inc. and Tirdad Rouhani.
    10.2   Executive Employment Agreement dated June 25, 2024, by and between Ispire Technology Inc. and Steven Przybyla.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Ispire Technology Inc.
         
      By: /s/ Michael Wang
        Name:  Michael Wang
        Title: Co-Chief Executive Officer
         
    Dated: June 28, 2024    

     

     

    4

     

     

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fargis John sold $14,625 worth of shares (7,500 units at $1.95), decreasing direct ownership by 16% to 39,099 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    11/24/25 4:30:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $45,001 worth of shares (17,046 units at $2.64), decreasing direct ownership by 4% to 399,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    10/2/25 4:30:03 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Cox Brent was granted 29,784 shares, increasing direct ownership by 142% to 50,782 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    7/11/25 4:31:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care